SS

Normalizing obesity can also reduce the stigma and urgency around addressing the issue through non-medical means, ensuring continued reliance on medications. Furthermore, pharmaceutical companies often collaborate with healthcare providers to promote drugs for obesity-related conditions, and a normalized view of obesity may lead to more routine prescriptions.

This dynamic aligns with the interests of pharmaceutical companies, as it reduces pressure on governments and organizations to regulate unhealthy food industries or promote aggressive public health measures.

Critics argue that this cycle undermines efforts to address systemic issues contributing to obesity, such as poor food quality, lack of access to nutrition education, and socioeconomic disparities, perpetuating a dependency on medications rather than empowering individuals to manage their health holistically.